14 October 2021 | Thursday | News
360biolabs®, the most comprehensive contract research organization in Australia and New Zealand, has now officially joined forces with BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. The acquisition of 360biolabs, known moving forward as 360biolabs® a BioAgilytix company, is now complete following Australian Foreign Investment Review Board (“FIRB”) approval.
Located in Australia’s biomedical and clinical research hubs, Victoria and Queensland, 360biolabs offers world-class virology and immunology expertise, with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities with a state-of-the-art flow cytometry suite, molecular biology PCR suite and expansive bioanalytical LC-MS/MS small molecule capabilities.
“Our team is thrilled to formally join forces with BioAgilytix, as we already share so much culturally, from our mutual strong scientific track record to our commitment to quality science enabling innovative medicines to be developed for patients. Together we will provide an exceptional range of specialized assays and services to fulfill our clients’ high expectations on a global scale,” said Alistair Draffan, CEO of 360biolabs. “We have no doubt that the combined group is more than up to the task of tackling the world’s many health challenges, whether the pandemic or treatments for unmet clinical needs.”
The acquisition of 360biolabs expands the BioAgilytix capability into first-in-human trials (FIH), early-phase clinical trials and adds further capacity by joining 360biolabs’ internationally recognized quality systems (ISO/IEC 17025, ISO 15189, GLP and GCLP) in Melbourne and Brisbane with the existing BioAgilytix laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California and Hamburg, Germany.
“We are delighted to announce the final close of the 360biolabs acquisition, as it’s such positive and exciting news for our global team and customers. Our expanded capacity, expertise and agility to now serve clients across all geographies is unprecedented,” said
Jim Datin, President and CEO of BioAgilytix. “360biolabs’ leadership position in virology and immunology, plus their small molecule capabilities and location in Melbourne and Brisbane, help make BioAgilytix an end-to-end bioanalytical force dedicated to helping generate new innovations and life-changing therapeutics for patients around the world.”
BioAgilytix selected White & Case as legal counsel to oversee the closing of the acquisition, and Lazard Australia and Allens represented 360biolabs.